Primary Immunodeficiency Diseases (PID) Clinical Trial
Official title:
A Phase 3, Open-label, Non-controlled, Extension Study to Evaluate the Long-term Safety of TAK-771 in Japanese Patients With Primary Immunodeficiency Disease (PID)
The main aim of the study is to check side effect from the study treatment with TAK-771 in long term. Participants can have taken part in the previous study TAK-771-3004 (NCT05150340). For those who can take part, the participants will receive injections of TAK-771 after the end of the previous study. The participants will be treated with TAK-771 for totally 3 years. There will be many clinic visits. The number of visits will depend on the infusion cycles of study drug.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03277313 -
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects
|
Phase 3 | |
| Completed |
NCT03716700 -
Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)
|
||
| Recruiting |
NCT05986734 -
Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies
|
||
| Completed |
NCT00546871 -
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05755035 -
A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases
|
Phase 2/Phase 3 | |
| Completed |
NCT02593188 -
Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)
|
||
| Completed |
NCT03116347 -
Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects
|
Phase 4 | |
| Completed |
NCT00157079 -
Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
|
Phase 3 | |
| Completed |
NCT01412385 -
Immune Globulin Subcutaenous (Human), 20%
|
Phase 2/Phase 3 | |
| Completed |
NCT00161993 -
Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)
|
Phase 2 | |
| Completed |
NCT01175213 -
Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID
|
Phase 3 | |
| Completed |
NCT01218438 -
Phase 2/3 Study of IGSC, 20% in PIDD
|
Phase 2/Phase 3 | |
| Completed |
NCT05150340 -
A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)
|
Phase 3 | |
| Not yet recruiting |
NCT06076642 -
A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases
|
Phase 3 | |
| Completed |
NCT00782106 -
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously
|
Phase 1/Phase 2 | |
| Completed |
NCT01485796 -
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06150534 -
At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill
|
||
| Completed |
NCT00814320 -
Gammagard Liquid and rHuPH20 in PID
|
Phase 3 | |
| Completed |
NCT04346108 -
A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)
|
Phase 3 |